72.19.Z - Scientific research and development activities
21.10.Z - Manufacture of basic pharmaceutical products
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
26.51.Z - Manufacture of measuring, controlling, and navigation instruments
26.60.Z - Manufacture of irradiation equipment, electromedical and electrotherapeutic equipment
58.11.Z - Publishing of books
71.20.B - Inspection and issuing opinions on the technical condition of chimneys and ventilation ducts
80.10.Z - Detective and security activities
85.42.B - Education
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 15,6 | 12,8 | -12,4 | -196,2 |
EBITDA | 34,1 | 32,3 | 20,7 | -35,9 |
Short time liabilities | 31,6 | 50,4 | 59 | 17,1 |
Equity capital | 261,4 | 273,9 | 261,1 | -4,7 |
Operating profit (EBIT) | 15,2 | 11 | -7,3 | -166,3 |
Assets | 684,1 | 771,9 | 869,8 | 12,7 |
Net profit (loss) | 15,3 | 12,5 | -12,8 | -202 |
Cash | 149,7 | 176,4 | 69,3 | -60,7 |
Net income from sale | 312 | 353,5 | 391,5 | 10,7 |
Liabilities and provisions for liabilities | 422,7 | 498 | 608,7 | 22,2 |
Working assets | 250,9 | 303,5 | 183,9 | -39,4 |
Depreciation | 19 | 21,3 | 28 | 31,6 |
% | % | % | p.p. | |
Profitability of capital | 5,8 | 4,6 | -4,9 | -9,5 |
Equity capital to total assets | 38,2 | 35,5 | 30 | -5,5 |
Gross profit margin | 5 | 3,6 | -3,2 | -6,8 |
EBITDA Margin | 10,9 | 9,1 | 5,3 | -3,8 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 37 | 52 | 55 | 3 |
Current financial liquidity indicator | 0.6347541213035583 | 0.643713653087616 | 0.3225545585155487 | -0,3 |
Net dept to EBITDA | -3.9941956996917725 | -5.155794620513916 | -1.9297572374343872 | 3,3 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane